Find Faculty Members at MUSC.

Mark Hamann

Mark T. Hamann

Provider Image
Rank
  • Professor
College
  • College of Pharmacy
Department
  • SCCP Drug Discovery and Biomedical Sciences - MUSC Campus
Academic Focus
  • The discovery and development of new natural products with activity against cancer, infectious disease and neurological disorders.
  • The development and application of state-of-the-art NMR and MS techniques that expedite the discovery, dereplication and structure assignment of new natural products.
  • The synthesis, medicinal chemistry and optimization of natural products with novel mechanisms of action against cancer, infectious disease and neurological disorders.

Locations

Office Location
street
room

Biography

Dr. Mark T. Hamann serves as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy.  He also holds Adjunct appointments with The University of Maryland’s Institute of Marine and Environmental Technology and the Bigelow Marine Laboratory in Maine.  Dr. Hamann began his career in GMP pharmaceutical manufacturing at Solvay Pharmaceuticals in Baudette, Minnesota and then completed a Ph.D. degree in Organic Chemistry at the University of Hawaii, under the guidance of the late Professor Paul J. Scheuer.  During his graduate studies he discovered the lead anticancer agent, kahalalide F which entered clinical trials with the help of the biotech company PharmaMar.  Dr. Hamann completed Postdoctoral Studies with Prof Bill Baker at McMurdo Station in Antarctica and then spent 20 years as a faculty member and natural products researcher at The University of Mississippi School of Pharmacy.  During his research career, Dr. Hamann has published over 200 scientific papers, reviews, book chapters and guided over 100 graduate students/postdoctoral fellows and visiting scholars.  Dr. Hamann currently serves as an Associate Editor for Biochimica et Biophysica Acta, General Subjects.  His group is actively involved in the isolation, structure determination and optimization through synthesis of natural products and toxins with a focus on plant and invertebrate microbiomes.  His group is currently working on the preclinical development of a small pipeline of natural products with activity against cancer, emerging infectious diseases and neuropsychiatric disorders.